DrugPatentWatch Database Preview
Covis Pharma Bv Company Profile
What is the competitive landscape for COVIS PHARMA BV, and when can generic versions of COVIS PHARMA BV drugs launch?
COVIS PHARMA BV has twelve approved drugs.
There are six US patents protecting COVIS PHARMA BV drugs.
There are one hundred and sixty-six patent family members on COVIS PHARMA BV drugs in forty-four countries and five supplementary protection certificates in two countries.
Summary for Covis Pharma Bv
International Patents: | 166 |
US Patents: | 6 |
Tradenames: | 12 |
Ingredients: | 8 |
NDAs: | 12 |
Drugs and US Patents for Covis Pharma Bv
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Covis Pharma Bv | BETAPACE AF | sotalol hydrochloride | TABLET;ORAL | 021151-007 | Apr 2, 2003 | DISCN | No | No | Start Trial | Start Trial | |||||
Covis Pharma Bv | ZANAFLEX | tizanidine hydrochloride | TABLET;ORAL | 020397-001 | Nov 27, 1996 | AB | RX | Yes | Yes | Start Trial | Start Trial | ||||
Covis Pharma Bv | LANOXIN | digoxin | INJECTABLE;INJECTION | 009330-002 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | Start Trial | Start Trial | ||||
Covis Pharma Bv | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-007 | Jan 2, 2008 | AB | RX | Yes | Yes | Start Trial | Start Trial | ||||
Covis Pharma Bv | LANOXIN PEDIATRIC | digoxin | INJECTABLE;INJECTION | 009330-004 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | Start Trial | Start Trial | |||||
Covis Pharma Bv | RILUTEK | riluzole | TABLET;ORAL | 020599-001 | Dec 12, 1995 | AB | RX | Yes | Yes | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Covis Pharma Bv
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Covis Pharma Bv | PRILOSEC | omeprazole magnesium | FOR SUSPENSION, DELAYED RELEASE;ORAL | 022056-001 | Mar 20, 2008 | 6,428,810 | Start Trial |
Covis Pharma Bv | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-006 | Jan 2, 2008 | 5,422,123 | Start Trial |
Covis Pharma Bv | ZETONNA | ciclesonide | AEROSOL, METERED;NASAL | 202129-001 | Jan 20, 2012 | 5,775,321 | Start Trial |
Covis Pharma Bv | RILUTEK | riluzole | TABLET;ORAL | 020599-001 | Dec 12, 1995 | 5,527,814 | Start Trial |
Covis Pharma Bv | SULAR | nisoldipine | TABLET, EXTENDED RELEASE;ORAL | 020356-007 | Jan 2, 2008 | 5,422,123 | Start Trial |
Covis Pharma Bv | PRILOSEC | omeprazole magnesium | FOR SUSPENSION, DELAYED RELEASE;ORAL | 022056-001 | Mar 20, 2008 | 5,690,960 | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for COVIS PHARMA BV drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Nasal Spray | 250 mcg | ➤ Subscribe | 2012-02-13 |
➤ Subscribe | Extended-release Tablets | 25.5 mg and 34 mg | ➤ Subscribe | 2008-11-28 |
➤ Subscribe | Extended-release Tablets | 8.5 mg and 17 mg | ➤ Subscribe | 2009-03-02 |
➤ Subscribe | Capsules | 2 mg, 4 mg and 6 mg | ➤ Subscribe | 2007-08-10 |
➤ Subscribe | Extended-release Tablets | 20 mg and 30 mg | ➤ Subscribe | 2007-11-07 |
➤ Subscribe | Extended-release Tablets | 40 mg | ➤ Subscribe | 2007-06-11 |
International Patents for Covis Pharma Bv Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Hong Kong | 1050858 | Start Trial |
Bulgaria | 65818 | Start Trial |
Peru | 07132001 | Start Trial |
Denmark | 0998916 | Start Trial |
Canada | 2538419 | Start Trial |
China | 1379674 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Covis Pharma Bv Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0984957 | SPC/GB11/013 | United Kingdom | Start Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
1411900 | 2011/016 | Ireland | Start Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105 |
0984957 | 2012/048 | Ireland | Start Trial | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
1411900 | SPC/GB11/015 | United Kingdom | Start Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
0124495 | SPC/GB01/006 | United Kingdom | Start Trial | PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.